Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene therapy injection aims to lower eye pressure in glaucoma patients

NCT ID NCT06921317

Recruiting now Disease control Sponsor: IVIEW Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 28 times

Summary

This early-stage trial tests a gene therapy called GVB-2001 for people with primary open-angle glaucoma, a common eye disease that damages the optic nerve due to high pressure inside the eye. The treatment is given as a single injection into the eye. The study will enroll 6 adults aged 18 to 75 to check if the therapy is safe and can lower eye pressure. It is not a cure, but aims to control the disease and reduce the need for other treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY OPEN ANGLE GLAUCOMA (POAG) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PRIMARY OPEN ANGLE GLAUCOMA (POAG)